David Cole to Genetic Therapy
This is a "connection" page, showing publications David Cole has written about Genetic Therapy.
Connection Strength
0.648
-
Bystander effect contributes to the antitumor efficacy of CaSm antisense gene therapy in a preclinical model of advanced pancreatic cancer. Mol Ther. 2006 Feb; 13(2):357-65.
Score: 0.216
-
CaSm antisense gene therapy: a novel approach for the treatment of pancreatic cancer. Anticancer Res. 2003 May-Jun; 23(3A):2007-13.
Score: 0.182
-
The cancer-associated Sm-like oncogene: a novel target for the gene therapy of pancreatic cancer. Surgery. 2000 Aug; 128(2):353-60.
Score: 0.151
-
EpCAM is overexpressed in breast cancer and is a potential target for breast cancer gene therapy. Cancer Res. 2004 Aug 15; 64(16):5818-24.
Score: 0.050
-
Paclitaxel tumor priming promotes delivery and transfection of intravenous lipid-siRNA in pancreatic tumors. J Control Release. 2015 Oct 28; 216:103-10.
Score: 0.027
-
Transferrin receptor targeting nanomedicine delivering wild-type p53 gene sensitizes pancreatic cancer to gemcitabine therapy. Cancer Gene Ther. 2013 Apr; 20(4):222-8.
Score: 0.023